Blue-toe and cholesterol embolisation syndromes

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Blue-toe syndrome is a clinical pattern: one or more painful cyanotic digits caused by occlusion of small arteries or arterioles. Pedal pulses may remain palpable because emboli lodge beyond the vessels being examined. The pattern is not synonymous with cholesterol embolisation. Platelet-fibrin or thrombotic debris can arise from ulcerated aortic or lower-limb plaque, aneurysm, graft, stent or cardiac source and often produces abrupt focal ischaemia. Other mimics include vasculitis, antiphospholipid disease, endocarditis, hyperviscosity, venous outflow obstruction and cold injury.

Cholesterol crystal embolisation is an athero-inflammatory shower from disrupted plaque in the aorta or a major branch. Crystals obstruct arterioles and provoke a foreign-body inflammatory response. It often follows angiography or vascular surgery, sometimes after antithrombotic or fibrinolytic exposure, but a direct causal link with anticoagulation alone is not established and spontaneous disease occurs. The combination of blue toes or livedo with subacute kidney injury, eosinophilia, low complement and systemic symptoms is strongly suggestive.

Management depends on the material and source. A discrete thromboembolic lesion may require urgent exclusion, repair, stenting, endarterectomy or bypass plus source-specific antithrombotic treatment. Established cholesterol showering has no proven crystal-dissolving medicine; care limits further plaque manipulation, treats cardiovascular risk, supports renal and other organ failure and considers source exclusion when a clear recurrent source can be treated safely. Anticoagulation decisions must preserve any independent compelling indication rather than follow a blanket rule.

Key points

Blue-toe syndrome describes painful blue or violaceous digits from small-vessel occlusion; palpable pedal pulses do not exclude it because proximal large arteries may remain patent.
Thromboembolic blue toe is often abrupt and source-related, whereas cholesterol crystal embolisation may evolve subacutely with livedo, kidney injury and inflammatory laboratory features.
Ask about recent angiography, vascular surgery and anticoagulant or thrombolytic exposure, while remembering that cholesterol embolisation can also occur spontaneously.
Image the arterial tree for unstable plaque, aneurysm, graft or cardiac source, but select the study to avoid unnecessary additional aortic instrumentation in suspected cholesterol showering.
Eosinophilia and low complement can support cholesterol embolisation but may be transient or absent; biopsy shows cholesterol clefts when diagnostic certainty will change care.
Treat tissue threat and correct an accessible embolic source; provide wound care, analgesia and atherosclerotic secondary prevention while supporting affected kidneys and other organs.
Do not start anticoagulation solely as treatment for cholesterol crystal embolisation, but do not apply an automatic stop rule when atrial fibrillation, prosthetic valve or acute thrombus provides another strong indication.
For thromboembolic disease, antiplatelet or anticoagulant therapy depends on the identified arterial, aneurysmal or cardiac source and any intervention performed.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Atherosclerotic plaque debris

Ulcerated aortic or limb plaque can release platelet-fibrin material or cholesterol crystals into digital arteries and arterioles.

Aneurysm or graft source

Mural thrombus within an aneurysm, failing graft or stent can repeatedly embolise distally while proximal flow and pulses persist.

Cardiac embolism

Atrial fibrillation, intracardiac thrombus, valve disease or endocarditis can send thrombotic or infective material into limb vessels.

Inflammatory and haematological mimics

Vasculitis, antiphospholipid syndrome, cryoglobulinaemia and hyperviscosity can occlude small vessels and reproduce a clinically similar blue-toe pattern.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Distal vessel occlusion
Small emboli travel through patent proximal arteries and lodge in digital arteries or arterioles, explaining tissue ischaemia despite palpable pulses.
2
Thrombus causes focal infarction
Platelet-fibrin debris commonly produces abrupt ischaemia in a defined territory and may respond to source-specific antithrombotic or procedural treatment.
3
Crystals provoke inflammation
Cholesterol clefts obstruct arterioles and trigger complement activation, eosinophilic inflammation, endothelial injury and progressive fibrosis around affected vessels.
4
Showering injures many organs
Aortic plaque disruption can distribute crystals to skin, kidneys, retina, gut and nervous system, producing a delayed multisystem syndrome.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Painful blue digitRed flag

Sudden blue or violaceous toe with pain, coolness or tenderness indicates digital ischaemia and warrants urgent vascular assessment.

Pulses may remainRed flag

Palpable dorsalis pedis or posterior tibial pulses are compatible with distal microembolisation and must not be used to dismiss blue-toe syndrome.

Cholesterol shower patternRed flag

Blue toes or livedo with subacute renal decline, constitutional symptoms and eosinophilia after arterial instrumentation suggests multisystem cholesterol embolisation.

Thromboembolic patternRed flag

Abrupt focal ischaemia after loss of a graft, aneurysm thrombosis or cardiac embolic event favours platelet-fibrin or thrombus material.

Retinal involvement

A Hollenhorst plaque supports cholesterol embolisation but can persist from an earlier event and does not date the current syndrome alone.

Infective source cluesRed flag

Fever, new murmur, splinter haemorrhages or positive cultures with digital lesions requires urgent assessment for infective endocarditis.

Red flags requiring action

Rapidly spreading digital cyanosis, rest pain, sensory or motor loss, or fixed tissue change indicates threatened tissue and needs immediate vascular review.
Blue toes with livedo reticularis, rising creatinine, eosinophilia or systemic symptoms after angiography suggests cholesterol crystal embolisation affecting multiple organs.
Fever, murmur, positive blood cultures or retinal and neurological emboli raises infective endocarditis and requires urgent sepsis and cardiac assessment.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Full vascular and digital examinationFirst step
Why
Define tissue viability and distinguish distal embolisation from whole-limb acute ischaemia.
Interpretation and limitations
Document each digit, skin temperature, refill, Doppler and proximal pulses; preserved pulses support distal disease but neither identify embolic material nor guarantee tissue safety.
02
Duplex ultrasound of source arteries
Why
Look for aneurysm, ulcerated plaque, stenosis, graft failure or thrombus without arterial instrumentation.
Interpretation and limitations
A plausible upstream lesion guides source control, but a negative regional study may require CTA or cardiac assessment because emboli can arise from the aorta.
03
CTA from aorta through pedal runoff
Why
Map aortic, iliac, femoropopliteal and aneurysmal sources plus runoff when intervention is considered.
Interpretation and limitations
Balance contrast and further instrumentation against renal injury and cholesterol-shower suspicion; urgent limb threat may still demand decisive imaging and treatment.
04
ECG and echocardiography
Why
Identify atrial fibrillation, intracardiac thrombus, valve disease or infective embolic source.
Interpretation and limitations
A cardiac source changes anticoagulation and infection treatment; a normal ECG alone does not exclude paroxysmal atrial fibrillation or aortic plaque.
05
Renal, inflammatory and haematology tests
Why
Detect multisystem cholesterol embolisation and exclude important inflammatory or infective mimics.
Interpretation and limitations
Trend creatinine, urine, blood count with eosinophils, CRP and complement; eosinophilia or low complement supports but absence does not exclude cholesterol embolisation.
06
Skin, muscle or renal biopsy
Why
Confirm cholesterol clefts when uncertainty materially changes high-risk treatment decisions.
Interpretation and limitations
Histology shows needle-shaped cholesterol clefts with inflammatory reaction; choose an accessible affected site and weigh wound, bleeding and sampling risk before biopsy.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Acute limb ischaemia

A larger arterial occlusion causes broader coldness, pulse or Doppler loss and neurological deficit, although distal emboli may coexist.

Vasculitis

Purpura, inflammatory organ disease and autoimmune features may mimic cholesterol embolisation; biopsy and targeted serology can separate vessel-wall inflammation.

Infective endocarditis

Fever, murmur, positive cultures, splenic or cerebral emboli and valve vegetation support infected emboli needing antimicrobial and cardiac treatment.

Cold and vasospastic disease

Raynaud phenomenon or cold injury is usually exposure-related and reversible early, without a proximal embolic lesion or progressive renal syndrome.

Venous congestion

Severe venous outflow obstruction produces cyanosis with swelling and venous signs rather than isolated arterial digital microinfarction.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Worked caseClassify a blue painful toeFirst stepA patient develops a painful purple toe with palpable pedal pulses two weeks after coronary angiography and creatinine is rising.

1Inputs: document timing, procedure route, skin distribution, whole-limb viability, pulses and Doppler, renal trajectory, urine, eosinophils, inflammatory markers and medicines.
2Reasoning: preserved pulses localise disease distally, while delayed renal decline plus cutaneous emboli after arterial instrumentation makes cholesterol crystal showering more likely than one large thrombus.
3Action: obtain urgent vascular and renal review, use non-invasive source imaging first where adequate, support organs and prevent avoidable further plaque instrumentation.
4Result: continue source-based tissue care and cardiovascular prevention, using biopsy only if uncertainty would materially change an intervention or immunosuppressive differential.
5Verification: trend digit viability, skin distribution, creatinine, urine output and systemic involvement while confirming that any antithrombotic plan has a documented independent indication.

02Thromboembolic pathwayFind and control a discrete sourceAbrupt focal digital ischaemia and imaging suggests thrombus, aneurysm, graft failure or an embolising arterial plaque.

1EscalationEscalate immediately if tissue threat extends beyond digits, and classify the entire limb rather than assuming all blue-toe presentations are minor.
2Define inflow and embolic source with duplex, CTA, angiography or cardiac studies selected for urgency, anatomy and kidney risk.
3Exclude, repair or reconstruct an accessible culprit lesion and prescribe antiplatelet or anticoagulant therapy according to the actual source and procedure.
4Monitor for recurrent showering, wound demarcation, infection and loss of a previously palpable pulse.

03Cholesterol pathwaySupport organs and reduce further showeringCutaneous microembolisation accompanies subacute kidney injury or systemic inflammatory features after plaque disruption or spontaneously.

1Avoid unnecessary repeat arterial instrumentation and seek vascular, renal and other organ-specific input while stabilising blood pressure, fluid status and tissue pain.
2Institute atherosclerotic secondary prevention, smoking treatment, foot protection and wound care, adapting blood-pressure and renal medicines to organ function.
3Do not initiate anticoagulation as cholesterol-crystal treatment; review rather than automatically stop it when a separate high-risk thrombotic indication exists.
4Consider source exclusion only when a culprit lesion is clear, embolisation recurs and procedural benefit outweighs the risk of provoking another shower.

04Alternative diagnosisTreat mimics on their evidenceAlternativeClinical pattern, cultures, autoimmune tests or vascular imaging supports infection, vasculitis, hypercoagulability or venous disease instead.

1Obtain blood cultures before antibiotics when infective endocarditis is plausible, unless septic instability requires immediate treatment under the sepsis pathway.
2Seek rheumatology or haematology input for vasculitic, antiphospholipid or hyperviscosity patterns before exposing ischaemic tissue to empiric immunosuppression.
3Keep vascular surveillance active because systemic disease and atherosclerotic embolisation can coexist in the same high-risk patient.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Reduces future atherothrombotic events but does not dissolve established cholesterol crystals in arterioles.

Antiplatelet therapy

For atherosclerotic peripheral arterial disease, prescribe the locally selected single antiplatelet agent at its licensed dose, commonly clopidogrel 75 mg orally once daily, unless source or procedure requires another regimen.

Check active bleeding, platelet count, interactions and planned biopsy or surgery. Do not present antiplatelet treatment as a proven reversal of cholesterol embolisation; duration and combinations depend on the vascular intervention and wider cardiovascular indication.

Treats the underlying atherosclerotic risk and may help stabilise remaining arterial plaque.

High-intensity statin

Use a high-intensity statin for established atherosclerotic disease, commonly atorvastatin 80 mg orally once daily, reducing or selecting an alternative for interactions, intolerance or specialist renal guidance.

Check liver disease, interacting medicines and muscle symptoms; severe renal dysfunction and frailty may alter selection. A statin supports secondary prevention but is not an acute antidote to lodged cholesterol crystals.

Treats thromboembolic risk when a clotting source exists; it is not treatment for cholesterol crystals themselves.

Source-directed anticoagulation

Dose and route depend on a separately established indication such as atrial fibrillation, prosthetic valve or acute thrombus; use the relevant national and local protocol with renal, bleeding and procedural adjustment.

Do not start solely for presumed cholesterol embolisation. Reports of temporal association do not prove universal causation, and automatic withdrawal can be dangerous when a strong independent indication exists; document multidisciplinary risk–benefit reasoning.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Digital tissue loss

Persistent microvascular occlusion causes ulceration, infection, dry gangrene and minor or major amputation despite preserved proximal arterial pulses.

Atheroembolic renal disease

Renal arteriole involvement causes subacute kidney injury, difficult hypertension, dialysis requirement and sometimes only partial renal recovery.

Recurrent embolisation

An untreated aneurysm, plaque, graft or cardiac source can send repeated showers, extending necrosis or affecting the contralateral limb.

Multiorgan ischaemia

Cholesterol crystals can involve retina, brain, gut and other organs, causing visual loss, neurological dysfunction, abdominal catastrophe and death.

Treatment-related harm

Further arterial manipulation can provoke another cholesterol shower, while inappropriate antithrombotic changes can cause bleeding or preventable thrombosis.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Photograph or diagram affected digits and livedo with consent, then record pain, temperature, capillary refill, Doppler and tissue demarcation at each review.
Trend creatinine, electrolytes, urine output and urinalysis after suspected cholesterol showering, because renal decline may be delayed and progressive.
Repeat full blood count with eosinophils, CRP and complement when clinically useful; remember that eosinophilia may be transient and normal results do not exclude disease.
Monitor for new abdominal pain, neurological change, visual symptoms, uncontrolled hypertension and systemic inflammation indicating additional embolised organs.
After source intervention, check for recurrent digital lesions, access complications, patency and kidney deterioration caused by contrast or renewed embolisation.
Review antiplatelet, anticoagulant and statin indications, doses, renal adjustment, bleeding risk and adherence at every transition of care.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Blue toe is a syndrome

The colour localises tissue injury but does not reveal whether the occluding material is cholesterol, platelet-fibrin thrombus or inflammatory debris.

Pulses localise calibre

Preserved pedal pulses suggest patent larger arteries while emboli obstruct digital vessels and arterioles; they do not make the lesion benign.

Timing helps classification

Abrupt single-territory infarction favours thromboembolism, whereas delayed renal decline and widespread livedo after instrumentation favours cholesterol showering.

Eosinophilia is supportive

An eosinophil rise can strengthen the cholesterol diagnosis but may be absent or transient and never substitutes for the overall pattern.

Contrast injury differs

Contrast-associated kidney injury usually starts within days, whereas atheroembolic renal disease often evolves more slowly with skin and systemic findings.

Anticoagulation needs an indication

Treat an established thrombotic source, but do not label anticoagulation as cholesterol-crystal therapy or stop it reflexively despite a prosthetic valve.

11Common pitfallsFrequent interpretation and management errors.

01
Reassuring a patient with a painful blue toe because dorsalis pedis and posterior tibial pulses are palpable.
02
Calling every blue toe cholesterol embolisation without evaluating arterial thrombus, aneurysm, cardiac embolus, endocarditis and vasculitis.
03
Attributing delayed kidney injury after angiography to contrast alone while ignoring livedo, eosinophilia or new digital lesions.
04
Ordering repeated invasive angiography before considering duplex or CTA and the risk of disturbing further aortic plaque.
05
Starting anticoagulation as a treatment for cholesterol crystals without finding a separate thrombotic indication.
06
Stopping necessary anticoagulation automatically in atrial fibrillation or a prosthetic valve without multidisciplinary assessment of competing risks.

Find your next topic